Sign In
Search Icon
Menu Icon

JYNNEOS Vaccine Distribution by Jurisdiction

Mpox National Vaccine Strategy


The U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR) is making a total of 1.1 million vials of Bavarian Nordic’s JYNNEOS, an FDA-licensed vaccine indicated for prevention of smallpox and mpox (formerly known as monkeypox), available for free to jurisdictions to support their local monkeypox response efforts. 

JYNNEOS was developed with the support of the Biomedical Advanced Research and Development Authority (BARDA) as one element of the federal government’s smallpox preparedness efforts. Prior to the mpox outbreak, the Strategic National Stockpile (SNS) held thousands of vials in its inventory, while millions more – either filled and finished or the equivalent in bulk substance – were stored at the manufacturer’s facility in Denmark. 

On August 9, 2022, the U.S. Food and Drug Administration authorized the emergency use of an alternative dosing approach that allows health care providers to use the vaccine from one vial of JYNNEOS vaccine to protect up to five people when administered intradermally to individuals 18 years of age or older. 

Since the start of the outbreak, ASPR has ordered 5.5 million vials of JYNNEOS from Bavarian Nordic to be filled, finished, and delivered from U.S. government-owned bulk vaccine stored in Denmark, bringing the U.S. government supply to approximately 7 million vials by mid-2023. Under the procurement, Bavarian Nordic agreed to complete a technology transfer that would allow for 2.5 million of those vials to be filled and finished by a U.S.-based contract manufacturer.

JYNNEOS Vaccine


Jynneos Vaccine Allocation

HHS is allocating JYNNEOS vaccine to meet the needs of at-risk individuals and prioritize the hardest-hit jurisdictions, which have high case burden and transmission rates for mpox. 

On August 22, 2022, an additional 360,000 vials of JYNNEOS vaccine were allocated to jurisdictions under phase 4 of the National Mpox Vaccine Strategy. Allocations for phase 4 are based on a revised strategy using cases reported (50% weight) to the Centers for Disease Control and Prevention (CDC) as of August 18, 2022, and the estimated size of the underlying population in the jurisdiction that might benefit from expanded vaccination at this point in the outbreak (50% weight). This underlying population currently includes gay, bisexual, and other men who have sex with men, people with HIV or who are eligible for HIV pre-exposure prophylaxis (HIV PrEP).

Distribution of vials will occur between August 22 and September 30, in three tranches, with each tranche comprised of one-third of the jurisdiction's phase 4 allocation. Jurisdiction may request access to tranches one, two, and three with an attestation to having utilized at least 85% of vials received to date.


JYNNEOS Delivered to Date

Data on JYNNEOS allocation, orders, and deliveries will be made public on Monday, Wednesday and Friday. Of note, some vaccine shipments exceed allocations due to distributions made prior to the implementation of HHS’s nationwide vaccine strategy. 

The below figures are for vials of JYNNEOS allocated, ordered, and delivered, and reflect amounts made available before and after the FDA issued the emergency use authorization allowing for intradermal vaccination, which allows for up to five doses per vial. As a result, the number of doses available and / or administered will vary depending on when vaccine was received by a jurisdiction and how it was administered to a patient.    

All data in the below table reflects vials of JYNNEOS vaccine.

JYNNEOS  Vials By Jurisdictions

Jurisdiction
Total Allocated Vials
as of Nov 28 2022, 12pm
Total Requested
as of Nov 28 2022, 12pm
Total Shipped
as of Nov 28 2022, 12pm
All Jurisdictions 1,091,630 855,873 855,693
Alabama 6,163 4,523 4,523
Alaska 660 600 600
American Samoa 40 40 40
Arizona 16,433 12,173 12,173
Arkansas 3,280 2,460 2,460
California 112,309 114,189 114,189
California - Los Angeles 73,802 65,522 65,522
Colorado 18,145 12,805 12,805
Connecticut 6,328 6,328 6,328
Delaware 1,895 1,655 1,655
District of Columbia 28,995 27,415 27,415
Federated States of Micronesia 20 20 20
Florida 112,680 74,720 74,720
Georgia 54,482 33,522 33,522
Guam 120 80 80
Hawaii 3,872 3,272 3,272
Idaho 2,000 1,380 1,380
Illinois 19,198 15,298 15,298
Illinois - Chicago 50,469 40,629 40,629
Indiana 11,872 7,812 7,812
Iowa 2,441 1,921 1,921
Kansas 2,156 2,156 2,156
Kentucky 6,140 4,100 4,100
Louisiana 11,882 8,862 8,862
Maine 1,411 1,291 1,291
Marshall Islands 20 20 20
Maryland 23,299 14,539 14,539
Massachusetts 24,451 18,591 18,591
Michigan 14,318 9,818 9,818
Minnesota 10,658 8,118 8,058
Mississippi 3,241 1,821 1,821
Missouri 9,073 6,053 6,053
Montana 778 478 478
Nebraska 1,641 1,421 1,421
Nevada 8,682 7,402 7,402
New Hampshire 1,467 1,187 1,187
New Jersey 22,269 16,149 16,149
New Mexico 3,436 3,016 3,016
New York 43,375 34,695 34,695
New York - New York City 118,444 103,104 103,104
North Carolina 20,288 16,688 16,688
North Dakota 555 435 435
Northern Mariana Islands 60 40 40
Ohio 18,713 12,573 12,573
Oklahoma 5,316 4,756 4,756
Oregon 11,498 10,838 10,838
Palau 20 20 20
Pennsylvania 16,747 13,831 13,731
Pennsylvania - Philadelphia 10,638 6,630 6,630
Puerto Rico 5,387 3,267 3,267
Rhode Island 4,014 2,774 2,774
South Carolina 6,387 4,287 4,287
South Dakota 1,711 291 291
Tennessee 17,602 6,762 6,762
Texas 50,814 43,314 43,314
Texas - Houston 27,026 14,146 14,146
Tribal Entities 93 - -
U.S. Virgin Islands 240 180 180
Utah 6,169 4,709 4,709
Vermont 2,006 846 846
Virginia 22,259 15,459 15,459
Washington 23,930 18,970 18,950
West Virginia 2,277 1,057 1,057
Wisconsin 5,614 4,534 4,534
Wyoming 321 281 281


*Jurisdictions may also request shipments of ACAM2000 vaccine, which is in much greater supply, but due to significant side effects is not recommended for everyone.